ÂÜÀòÂÒÂ×

Pu Shi is a seasoned professional in the healthcare investment sector, currently serving in Healthcare Investment at Qiming Venture Partners since May 2022. Prior experience includes holding the position of Director and Head of Research Strategy and Innovation at BeiGene from September 2019 to May 2022, where leadership was provided in external innovation efforts and R&D portfolio diversification. At Takeda, Pu Shi advanced from Research Scientist to Group Head and Project Representative from August 2015 to August 2019, managing translational research and bioassay support for immuno-oncology. Co-founding and leading ReDesygn Laboratory LLC focused on novel antibody-based oncology biologics discovery occurred from September 2014 to August 2015. Educational credentials include a Bachelor of Science in Biology and a Bachelor of Economics from Peking University, along with a Ph.D. in Pharmaceutical Sciences from the University of Southern California.